Pancreatic Cancer in Europe & Central Asia
Death rates for Pancreatic Cancer across 58 countries in Europe & Central Asia.
| # | Country | Rate |
|---|
Pancreatic cancer is one of the most lethal malignancies, killing approximately 466,000 people annually with a five-year survival rate of only 10-12%. Pancreatic ductal adenocarcinoma accounts for over 90% of cases. The disease is characterised by late presentation, rapid progression, and resistance to most therapies. Incidence is highest in high-income countries and increases sharply with age. Tobacco smoking is the strongest modifiable risk factor, approximately doubling risk. Other risk factors include chronic pancreatitis, obesity, type 2 diabetes, heavy alcohol use, and family history. The lack of effective screening methods and the anatomical inaccessibility of the pancreas mean that most cases are diagnosed at stage III or IV when surgery is no longer curative. Despite decades of research, pancreatic cancer mortality has barely improved, making it the focus of intensive efforts to develop early detection biomarkers and novel therapeutic approaches. Europe and Central Asia benefit from relatively strong health systems and high physician density, but face ageing populations, rising non-communicable disease burdens, and persistent East-West health outcome gradients. In Europe & Central Asia, pancreatic cancer mortality is near global averages, though the region exhibits a marked gradient between Western European countries with low rates and Central Asian nations facing higher burdens.
Smoking cessation reduces pancreatic cancer risk. Maintaining a healthy weight and limiting alcohol intake are additional preventive measures. There is no recommended population-level screening programme, though surveillance with endoscopic ultrasound and MRI is offered to high-risk individuals (those with hereditary pancreatitis or familial pancreatic cancer syndromes). Surgical resection (Whipple procedure) offers the only chance of cure but is feasible in only 15-20% of patients at diagnosis. FOLFIRINOX and gemcitabine-nab-paclitaxel improve survival in advanced disease, and immunotherapy shows promise in mismatch repair-deficient tumours.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for pancreatic cancer in Europe & Central Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For pancreatic cancer across Europe & Central Asia, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.